Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

What drives operational performance in clinical R&D?

Nature Reviews Drug Discovery volume 15, pages 155–156 (2016)Cite this article

Subjects

Analysis

Our data set derives from benchmarking of 14 biopharmaceutical companies, which provided access to detailed quantitative information from their internal systems, as well as qualitative and quantitative information from interviews with leaders of development and clinical operations. The companies varied widely in size, with annual R&D spending of between ∼US$200 million and >$5 billion. Their combined R&D spending in 2014 was >$50 billion, representing a significant fraction of industry activity. For each of these companies, we analysed the 2013 and 2014 data on Phases I–III and Phase IV interventional trials across all therapeutic modalities (including therapeutic vaccines but excluding prophylactic ones).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Variation in performance among 14 companies.

Author information

Authors and Affiliations

  1. Boston Consulting Group, Exchange Place, Boston, 02109, Massachusetts, USA

    Michael Ringel, Valery Panier, Maria Denslow & Lorenna Buck

  2. The Boston Consulting Group, Münstergasse 2, 8001, Zürich, Switzerland

    Ulrik Schulze

  3. KMR Group, 150 North Wacker Drive, Chicago, 60606, Illinois, USA

    Linda Martin & Conrad Hawkins

Authors
  1. Michael Ringel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Linda Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Conrad Hawkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valery Panier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Denslow
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lorenna Buck
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ulrik Schulze
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Michael Ringel or Linda Martin.

Ethics declarations

Competing interests

The authors are employees of The Boston Consulting Group (BCG) and KMR Group, two organizations that consult with the world's leading biopharmaceutical companies on clinical R&D activities. The research for this specific article was funded by participating benchmark companies, BCG's health care practice and KMR Group.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ringel, M., Martin, L., Hawkins, C. et al. What drives operational performance in clinical R&D?. Nat Rev Drug Discov 15, 155–156 (2016). https://doi.org/10.1038/nrd.2016.2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2016.2

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research